Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo plus FLOT. The MATTERHORN trial showed consistent survival benefits across ...
Sir: So, Goodluck Jonathan is said to be eyeing a return to Aso Rock — again. The man who presided over one of the most rudderless, corrupt, and visionless administrations in Nigeria’s democratic ...
A close relative of Goodluck Jonathan, Azibaola Robert, has claimed that the former president is constitutionally and legally qualified to contest the 2027 Nigerian general elections. This statement ...
The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the respective ...
When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. After questioning the benefits of checkpoint inhibitors in stomach cancer cases without ...
DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of ...
The MATTERHORN trial showed improved EFS and OS with durvalumab plus chemotherapy in gastric/GEJ cancer patients compared to chemotherapy alone. Durvalumab treatment resulted in a higher pCR rate and ...
SANTA CLARA, Calif., April 17, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the ...
Former President Goodluck Jonathan, has criticised the suspension of elected officials in Rivers State by President Bola Tinubu. Jonathan said the move is capable of denting the country’s image. The ...
When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...
The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in EFS with the durvalumab regimen vs the placebo regimen. Topline results were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback